AB Science is stopping a late-stage clinical trial testing its oral drug masitinib as a treatment for progressive forms of multiple sclerosis (MS), saying this study and the therapy’s clinical development for MS are no longer a priority for the company. Instead, the developer will advance masitinib for…
Masitinib
Recommended Posts
- Review study links physical disability to cognitive problems in MS
- B-cell therapies linked to fewer relapses in early MS, study finds
- Physical activity programs for people with MS show promise, review finds
- Experimental CAR T-cell therapy shows promise in early MS trial
- MS patients show ‘vaccine fatigue’ after pandemic, German study finds